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Objectives: The internet is a valuable resource for accessing health information 
and support. This study aimed to develop a tool (the eHIQ) to measure the impact 
of using health-related websites which contain experiential and factual informa-
tion. MethOds: A multi-method study with four stages. Stage 1: Themes concern-
ing the impact of using health-related websites were identified through qualitative 
secondary analysis of interviews exploring patient and carer experiences of health 
and a relevant literature review. Stage 2: Questionnaire items based upon identified 
themes were constructed and assessed using expert and patient opinion. Stage 
3: Items were administered online and subjected to exploratory factor analysis. 
Stage 4: The reduced questionnaire and appropriate reference measures were 
administered online to test convergent validity and external reliability. Results: 
Sixty-seven items were constructed according to the key themes identified through 
relevant literature and qualitative analysis. Following expert and patient refinement, 
two independent item pools were entered into psychometric testing. The first item 
pool (eHIQ-Part 1) related to general views of using the internet in relation to health 
and second item pool (eHIQ-Part2) related to the impact of using a specific health-
related website. Analysis confirmed three domains present in eHIQ-Part 1 and six 
domains present in eHIQ-Part 2. These domains were tested further during Stage 4 
and were found to have high convergent validity, internal consistency and good test-
retest reliability. cOnclusiOns: Developing the eHIQ through the use of qualitative 
analysis and patient-expert opinion enhanced face and content validity. The eHIQ 
demonstrates good psychometric properties and will enable the measurement of 
the effects of using health-related websites across a range conditions.
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Objectives: Physicians treating systemic lupus erythematosus (SLE) use a variety 
of tools to monitor disease activity and organ damage however these do not capture 
the functional burden experienced by patients. Studies suggest that communication 
between physicians and patients need to be optimized. The Lupus Impact Tracker 
(LIT), a brief, disease specific 10-item patient reported outcome tool, was developed 
to assess the impact of SLE on patients daily functioning and well-being. This study 
aims to evaluate the cross-cultural validity, acceptability and feasibility of the LIT in 
European clinical practice settings. Potential effect of LIT on communication during 
the consultation will also be assessed. MethOds: This is a prospective, observa-
tional, multicenter cross-sectional validation study of SLE patients on standard of 
care from hospital/clinical settings in five European countries (France, Germany, 
Italy, Spain and Sweden). 625 patients enrolled to obtain at least 500 evaluable cases 
irrespective of disease severity. Before the visit, patients will complete self-reported 
questionnaires: SF-36, Global Evaluation of Change (GEC), care satisfaction and LIT. 
During visits, physicians will record patient data, assess disease activity using the 
SELENA-SLEDAI and Physician Global Assessment (PGA), and disease damage using 
the SLICC/ACR damage index. After the visit patients and physicians complete LIT 
feedback questionnaires. Analyses will be performed using descriptive statistical 
methods with no specific hypothesis suggested. Results: Psychometric evalua-
tion of LIT in US clinical settings found the tool reliable and valid. Evaluation for 
use in European clinical practice settings is thus needed. Cross-cultural validity 
of LIT across countries will be analyzed using differential item functioning (DIF) 
analysis. Data from the Lupus Impact Tracker-(Patient and Physician) Feedback 
Questionnaires will be tabulated and summarized. cOnclusiOns: We need 
improvement of the patient/physician interaction in lupus care. The LIT may be 
a valid and acceptable tool for use with SLE patients in European clinical practice 
settings.
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Objectives: To screen food-related products and support allegation demands, evalu-
ating food-related concepts with appropriate tools is essential. In the absence of such 
a tool, we developed a specific questionnaire providing insight into the way a person 
links food to well-being in terms of pleasure, joint comfort, digestive comfort, pre-
vention and immunity. MethOds: Semi-directive interviews were conducted with 
40 healthy subjects to explore three themes: food, well-being and food-related well-
being, and determine the basis of the interview guide for focus group discussions. 
Twenty-four group discussions (199 subjects in total) were conducted with healthy 
subjects (n= 12) and subjects with joint, digestive or repetitive infection complaints 
(n= 4 per complaint), to investigate definition and experience of food-related well-
being. Qualitative analysis was performed to identify concepts of interest. Based on 
the designed conceptual model and discussion with the scientific committee, items 
were generated using subjects’ verbatim expression. Face-to-face cognitive interviews 
were conducted with 29 healthy subjects to ensure comprehension and appropri-
Objectives: This research explored the feasibility of using mobile technology 
(mHealth) to capture data such as resource utilisation and patient reported 
outcomes to support the market access of new products. The main objectives 
were to understand best practices in engaging end users to optimise data col-
lection, and to explore payer opinions on the validity of using mHealth for 
data collection and its usefulness in the decision making process. MethOds: 
Secondary research was conducted to identify best practices in optimising 
end user engagement with mHealth solutions. Studies that led to success-
ful outcomes were analysed in detail to understand the key engagement suc-
cess factors. Qualitative primary payer interviews were conducted in several 
key European markets to understand the validity of using mHealth to collect 
data including perceived challenges of leveraging this data to support market 
access decisions. Results: Research showed that interventions that are person-
alised through data, analytics and behaviour change methodologies are most 
successful in engaging end users when using mHealth. Payers highlighted sev-
eral key concerns of using mHealth; namely, data quality and sustainability/ 
scalability. These concerns should be considered and addressed by health care 
companies who wish to use mHealth as a data platform to support payer deci-
sions. cOnclusiOns: mHealth is a tool that holds promise for many different 
parts of the health care value chain. This includes leveraging mHealth to support 
the market access targets of new products, by collecting and using data to enhance 
the communication of the products’ value. The findings from this research high-
light best practices to engage users in order to optimise data collection as well as 
provide insights from payers on the key concerns of doing so.
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Objectives: In 2010, the National Institute for Health and Clinical Excellence 
(NICE) performed a multiple technology assessment for second line biologic 
treatments (following the failure of a TNF inhibitor and disease modifying anti-
rheumatic drugs (DMARDs)) for the treatment of rheumatoid arthritis (RA). The 
Birmingham RA Model (BRAM) was used to obtain incremental cost-effectiveness 
ratios (ICERs) of £21,100/quality-adjusted life year (QALY) for rituximab versus 
DMARDs and £130,600 for abatacept versus rituximab. Adalimumab, etanercept 
and infliximab were dominated by rituximab. NICE recommended rituximab, 
unless contraindicated, in which case all the other biologics were recommended. 
The BRAM used in the NICE assessment used a linear regression model to trans-
late Health Assessment Questionnaire (HAQ) scores into EQ-5D scores, however 
other algorithms exist. The objective of this study was to understand how the 
algorithm used to map from HAQ to EQ-5D affects the ICERs generated by the 
model. MethOds: The BRAM used in the NICE assessment used a linear regres-
sion model to translate Health Assessment Questionnaire (HAQ) scores into EQ-5D 
scores, however other algorithms exist. The objective of this study was to under-
stand how the algorithm used to map from HAQ to EQ-5D affects the ICERs gen-
erated by the model. Results: The ordering of the effectiveness of treatments 
did not change with the mapping algorithm used, however there was substantial 
variation in the magnitude of the ICER. The ICER for rituximab versus DMARDs 
varied from £21,594/QALY to £32,039/QALY depending on the exact algorithm used. 
The ICER for abatacept versus rituximab varied from £124,776/QALY to £167,687/
QALY. cOnclusiOns: The cost-effectiveness results of the BRAM are heavily 
influenced by the choice of mapping algorithm. In future modelling, the choice 
of algorithm should be justified, and appropriate sensitivity analyses presented. 
Further research is needed to identify the most appropriate algorithm(s) for use 
in health technology assessment.
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Objectives: Disease-specific patient-reported outcomes (PROs) are designed to 
be highly relevant to a single disease. It is widely believed that comparisons of 
outcomes between patients with different diseases is only possible using generic 
PRO measures. The present study employs a novel method of using Rasch analy-
sis to co-calibrate scores from different disease-specific PROs allowing scores to 
be compared across diseases. MethOds: Three samples of patients completed 
the Asthma Life Impact Scale (ALIS), the Living with COPD scale (LCOPD) or the 
Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), depending on 
their illness. Each scale utilises the needs-based model of QoL and the scales 
share 8 common items. The three samples were analysed separately for fit to 
the Rasch model and then combined and re-analysed. Results: The ALIS was 
completed by 140 asthma patients (mean age= 50.6, males = 29.3%); the LCOPD 
by 162 COPD patients (mean age= 69.3, males = 43.8%) and the CAMPHOR by 91 
patients (mean age= 52.6, males = 29.7%). Each of the scales fit the Rasch model 
individually (ALIS Chi2 = 0.05; LCOPD Chi2 = 0.32; CAMPHOR Chi2 = 0.92). The com-
bined dataset also fit the Rasch model at first run (Chi2 = 0.24). One common item 
showed misfit (Chi2< 0.001) and non-uniform differential item functioning (DIF) 
by disease (Chi2< 0.001). This item was removed from the analysis and the final 
co-calibrated scale showed good fit to the Rasch model (Chi2= 0.48) with minimal 
DIF by age, gender or disease. cOnclusiOns: The results showed that it was pos-
sible to co-calibrate scores on the ALIS, LCOPD and CAMPHOR. As disease-specific 
measurement has advantages over generic assessment related to relevance and 
reproducibility, the results have the potential to enhance PRO measurement in 
respiratory research.
